Neoplasms

Symptoms and General Pathology

All Conditions

Heart and Blood Diseases

Blood and Lymph Conditions

Neoplasm Metastasis

Carcinoma

Thrombosis

Thromboembolism

Thrombophilia

Embolism

Embolism and Thrombosis

Vascular Diseases

coagulation study

immunoenzyme technique

laboratory biomarker analysis

physiologic testing

study of high risk factors

McDonald K. Horne, MD

RATIONALE: A test that detects abnormal blood clotting in patients with cancer may help doctors plan cancer surgery.

PURPOSE: This laboratory study is looking at a new blood test to detect abnormal clotting in patients with metastatic cancer undergoing surgery.

OBJECTIVES:

Primary

* Determine whether whole blood thrombin generation assay (WBTGA) detects hypercoagulability in patients with metastatic carcinoma compared with a healthy control group.
* Determine whether results of the WBTGA will change as a result of major surgery performed on patients with metastatic carcinoma.
* Establish a reference interval for the WBTGA using healthy controls.

Secondary

* Compare a battery of plasma components known to affect or reflect coagulant or fibrinolytic reactions in patients with metastatic carcinoma vs healthy controls.
* Establish reference intervals for this battery of tests using healthy controls.
* Determine how major surgery in cancer patients affects this battery of factors.
* Identify changes in these factors that correlate with changes in the WBTGA.
* Compare the results of WBTGA tests in patients who develop venous thromboembolism (VTE) with those who do not.

OUTLINE: This is a pilot study.

Blood samples of patients are collected on day -7 and day 1 after surgery.

Blood samples of healthy controls are collected once.

After collection, blood samples are analyzed for hypercoagulability by whole blood thrombin generation assay. Routine blood tests are performed, as are immunoenzyme techniques for antigenic tissue plasminogen activator and its inhibitor, thrombin-antithrombin complexes, tissue factor, factor VIIa, D-dimer, and glycocalicin.

PROJECTED ACCRUAL: A total of 30 patients and 30 healthy controls will be accrued for this study.

Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery

Evaluation of a Novel Blood Test Hypercoagulability in Surgical Patients With Metastatic Carcinoma: A Pilot Study

National Cancer Institute (NCI)

Antineoplastic Agents

All Drugs and Chemicals

Bevacizumab

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

bevacizumab

platelet aggregation test

Roger von Moos, MD

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about the effect of bevacizumab and VEGF on platelet clustering.

PURPOSE: This research study is looking at the effect of bevacizumab and VEGF on platelet clustering in patients with cancer who are receiving bevacizumab.

OBJECTIVES:

* To determine the influence of bevacizumab on platelet aggregation in patients receiving bevacizumab for cancer.
* To determine the influence of VEGF on platelet aggregation.
* To determine the influence of VEGF or bevacizumab on cyclooxygenesis.
* To determine if the sequence of medication plays a role in platelet aggregation.

OUTLINE: Blood samples are collected before and after bevacizumab infusion. Samples are analyzed for measurements of platelet aggregation, coagulation parameters, and endothelial activation (e.g., fibrin fragment F1 and 2, thrombin and antithrombin complex, soluble P-selectin, Von Willebrand factor and factor VIII, tissue factor, and endothelin 1).

Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer

Influence of Bevacizumab and VEGF on Platelet Aggregation

Kantonsspital Graubuenden

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery	NCT00096590	Thromboembolism Unspecified Adu...	coagulation stu... immunoenzyme te... laboratory biom... physiologic tes... study of high r...	18 Years -	National Cancer Institute (NCI)
Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer	NCT00898794	Unspecified Adu... Unspecified Chi...	bevacizumab coagulation stu... laboratory biom... platelet aggreg...	-	National Cancer Institute (NCI)
Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery	NCT00096590	Thromboembolism Unspecified Adu...	coagulation stu... immunoenzyme te... laboratory biom... physiologic tes... study of high r...	18 Years -	National Cancer Institute (NCI)

Spots Global Cancer Trial Database for coagulation study